Leadership Medica

Articolo

Angiogenesi terapeutica: una nuova possibilita` per il paziente ischemico
Therapeutic angiogenesis: a new choiche for ischemic patients

Autore

Tonino Bombardini

Bibliografia

1. Rakusan K. Coronary angiogenesis. From morphometry to molecular biology and back. Ann NY Acad Sci, 1995 Mar, 752: 257-66
2. Rakusan K, Cicutti N, Kazda S et al. Effect of nifedipine on capillary geometry in normotensive and hypertensive rats. Hypertension, 1994, 24:2, 205-211
3. Schaper W, Sharma HS, Quinkler W, et al: Molecular biologic concepts of coronary anastomoses.J Am Coll Cardiol 15:513-518, 1990.
4. Yanagisawa-Miwa A, Uchida Y, et al: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401-1403, 1992.
5. Unger EF, Banai S, Shou M, et al: Basic fibroblast  growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 266:H1588-H1595, 1994.
6. Banai S, Jaklitsch MT, Shou M, et al: Angiogenic induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183-2189, 1994.
7. Ferrara N, Houck KA, Jakman LB, et al: Molecular  and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 13: 18-32, 1992.
8. Kass RW, Kotler MN, Yazdanfar S: Stimulation of   coronary collateral growth: Current developments in  angiogenesis and future clinical applications. Am Heart J 123 :486-496, 1992. 
9. Maseri A: Experimental models of acute myocardial ischemia. In Ischemic Heart  Disease, ed by Maseri A. London: Churchill Livingstone, 1995, pp 139-162
10. Schaper W: The Collateral Circulation of the Heart. New York: Elsevier, 1971. 
11. Khouri EM, Gregg DE, McGranaham GM: Regression and reappearance of coronary collaterals. Am J Physiol 220:655, 1971. 
12. Lambert PR, Hess DS, Bache RJ. Effect of exercise on perfusion of collateral-dependent myocardium in dogs with chronic coronary artery occlusion. J Clin Invest 59: 1-11, 1977
13. Feldman RL, Pepine CJ. Evaluation of coronary collateral circulation in conscious humans. AM J Cardiol 53: 1233-1238, 1984
14. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary occlusion in human subjects: a prospective study. Circulation 74: 469-476, 1988
15. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327: 1825-1831, 1992
16. Sasayama S, Fujita M: Recent insights into coronary collateral circulation.
17. Sasayama S: Effect of coronary collateral circulation on myocardial ischemia and ventricular disfunction. Cardiovasc Drugs Ther 8: 327-334, 1994
18. Dreglid E, Larsen T, Srlie D: Collateral arterial capacity following acute iliac occlusion in the rat. Res Exp Med(Berl) 182:2, 177, 1983.
19. Sunakawa M, Kohnoto T, Kohomoto Y: Evaluation of tissue perfusion in ischemic legs of dogs by CO2 clearance rate  Acta Med Okayama 43:1, 47-54, 1989
20. Voigt H, Reuter W, Kohler H, Scheel H: Development of collateral circulation in arterial occlusions in advanced age. Z Gesamte Inn Med, 39:13, 311, 1984
21. Mall G, Schikora I, Lattfcklt T, et al: Dipyridamole induced neoformation of capillares
22. Syrnons JD, Firozmand E, Longhurst JC: Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise: a role for adenosine. Circ Res 73:503-513, 1993.
23. Azizkhan RG, Azizkhan JC, Zetter R, et al: Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 152:931-944, 1980.
24. Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297:307-312, 1982.
25. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313:355-364, 1992.
26. Schott R.J, Morrow  LA: Growth factors and angiogenesis.Cardiovasc Res 27:1155-1161, 1993.
27. Folkman J, Klagsbrun M, Sasse J, et al: A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 130:393-400, 1988.
28. Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64:867-869, 1991.
29. Ferrara N, Houck KA, Jakman LB, et al: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 13: 18-32, 1992.
30. Brogi E, Wu T, Namiki A, et al: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hipoxia upregulates VEGF expression only. Circulation 90: 649-652, 1994.
31. D'Amore PA, Thompson RW: Collateralization in peripheral vascular disease. In: Vascular Disease, ed. by Strandness DE, Didisheim P, Clowes AW, et al. New York: Grune and Stratton, 1987, pp 319-333.
32. Stravri GT, Zachary IC, Baskerville PA, et al: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells.Circulation 92:11-14, 1995.
33.Fujita M, Sasayama S, Asanoi H, et al: Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 77: 1022-1029, 1998
34. Fujita M, Yamanishi K, Hirai T, et al: Comparative effect of heparin treatment with and without strenous exercise on treadmill capacity in patients with stable effort angina. Am Heart J 122: 453-457, 1991
35. Quyyumi AA, Diodati JG, Lakatos E, et al: Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study. J Am Coll Cardiol 22: 635-641, 1993
36.Y. Mannarino E, Pasqualini L, Innocente S, et al: Efficacy of low molecular weight heparin in the management of intermittent claudication. Angiology 42: 1-7, 1991
37. Andreozzi GM, Signorelli SS, Cacciaguerra G, et al: Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche -Fontaine IIb Class. Angiology 4:307-13, 1993
38. Cina G,Vernich M,Campisi C,et al: Physical training and low-dose heparin-calcium in patients suffering from chronic obliterating arteriopathy of the lower limbs with intermittent claudication. Minerva Cardioangiol 44: 179-85,1996
39. Saito K,Mori S,Iwakura M, et al. Immunoistochemical localization of transforming growth factor beta, basic FGF, and heparan sulfate in gingival hyperplasia induced by nifedipine and phentoin. J Periodontal Res, 1996, 31:8,545-55
40. Opie LH,Frishman WH,Thadani U. Calcium Channel Antagonists; in Drugs fot the Heart, fourth edition 1997, by Lionel H Opie, W B Saunders Company, chapter 3, 50-82
41. Kohn EC, Alessandro R, Spoonster J, et al. Angiogenesis: role of calcium mediated signal transduction. Proc Natl Acad Sci USA, 1995 Feb, 92:5, 1307-11
42. Eickelberg O, Roth M,Mussmann R, et al. Calcium channel blockers activate interleukine -6 gene via the transcription factors NF-IL6 and NF-kb in primary human vascular smooth muscle cells. Circulation, 2276-2282, 1999
43. Dusseau JW,Hutchins PM,Malbasa DS. Stimulation of angiogenesis by adenosine on chick chorioallantoic membrane. Circ Res.1986; 59:163-170
44. Ziada AMAR, Hudlicka O, Tyler KR, et al. The effect of long-term vasodilation on capillary growth and performance in rabbit heart and skeletal muscle. Cardioascular Res 1984; 18:724-732
45. Ziche M, Parenti A, Ledda F, Dell'era P, Granger HJ, Maggi CA, Presta M. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997; 80: 845-852
46. Picano E. Dipyridamole-echocardiography test: the historical background and the physiologic basis. Eur Heart J 1989; 10: 365-376
47. Meininger CJ, Schelling ME, Granger HJ. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am J Physiol 1988; 255: H544-62
48. Meininger CJ, Granger HJ. Mechanisms leading to adenosine - stimulated proliferation of microvascular endothelial cells. Am J Phisiol 1990; 258: H 198-H206
49. Mattfeld T, Mal G. Dipyridamole-induced capillary endothelial cell proliferation in the rat heart:  a morphometric investigation. Cardiovasc Res 1983; 17: 229-237
50. Symons JD, Firoozmand E, Longhurst JC. Repeated dipyridamole administration enhances collateral-dependent flow and regional function during exercise. A role of adenosine. Circulation Res 1993; 73: 503-513
51. Sacks HS, Ancona-Berk VA, Berrier J, et al. Dipyridamole in treatment of angina pectoris: a meta- analysis. Clin Pharmacol Ther 1988; 43: 610-615
52. Cumberland D, Virmani R. Myocardial revascularization by angiogenesis. Online coverage from the Am Coll Cardiol, 48th annual scientific session, march 1999
53. Isner JM, Pieczec A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF 165 in patient with ischemic limb. Lancet 348(9024): 370-4, 1996
54. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of ph VEGF165 following intramuscolar gene transfer promotes collateral vessel development in patients with crtical limb ischemia. Circulation 97: 1114-1123, 1998
55. Tsurumi Y, Takesita S, Chen D, et al. Direct intramuscolar gene transfer of naked DNA encoding vascular endothelial, growth factor augments collateral development and tissue perfusion. Circulation 94(12):3281-90, 1996
56. Vale PR. VEGF gene transfer works as sole thearpy for medically resistant angina. Am Heart Ass, 71st Scientific session, November 1998.